Bio-Gate signs cooperation agreement with Aesculap AG for coating revision implants

Nuremberg, 24 June 2020 - Bio-Gate AG (ISIN DE000BGAG981), one of the world's leading providers of innovative technologies and individual solutions for health and hygiene, has signed an extensive cooperation agreement with Aesculap AG, one of the world's leading suppliers of implants, and a subsidiary of B. Braun, for the antimicrobial coating of revision implants for knee and hip systems. The agreement also includes an option for using the HyProtect™ coating technology in other application areas.

The cooperation agreement is internationally oriented and is based on several years of trustworthy collaboration between Bio-Gate and Aesculap on various coating projects.  In recent years, the companies have successfully worked together on several studies.  This includes an already published osseointegration study, in which the healing process of the bone ingrowth in implants in human bone was investigated.  Over the course of the study, the HyProtect™ coating demonstrated a very good bone ingrowth performance. 

The basis for this cooperation was the successful completion of the preliminary development project for the application of the HyProtect™ coating on Aesculap implants. After completion of regulatory approvals, Bio-Gate will coat Aesculap's implants. The cooperation agreement will contribute a significant growth to Bio-Gate's coating business.

To date, over 60 single patient human cases have been successfully completed - validating the high antimicrobial effectiveness and quality of Bio-Gate’s coating. The implants were primarily used in orthopedic revision surgeries for patients with a high risk of infection. In all cases to date, the patients have remained free of infection. This is crucial for the healing process in these patient groups since re-infections can lead to amputations or even have life-threatening consequences. Further clinical studies to confirm the clinical evidence are planned.

Besides human medicine, Bio-Gate is also actively coating veterinary implants. In recent years, more than 60,000 dogs have been successfully treated with antimicrobial HyProtect™ coated implants. The overall infection rate was merely less than 0.4 percent. In normal practice, infection rates of up to 20 percent are not uncommon.

Similarly, one key focus of the cooperation partners is to significantly reduce the risk of infection for patients. With the finalized agreement in place, Aesculap can already now start the approval process for certain implants. 

Contacts:
Bio-Gate AG / Neumeyerstr. 28-34 /D-90411 Nürnberg
www.bio-gate.de

Gerd Rückel
rikutis consulting 
gr@rikutis.de
presse@bio-gate.de
Tel +49 (0) 6172 807309
Mobil +49 (0)152 34221966

Aesculap AG / Am Aesculap Platz / D-78532 Tuttlingen
www.bbraun.de
Felicitas Janßen
presse@aesculap.de
Tel. +49 (0) 7461 95-1082